NetworkNewsBreaks – Oncotelic Therapeutics, Inc.
Post# of 71
(Total Views: 45)
Posted On: 10/31/2025 6:12:12 PM
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present Sapu003 Data at 2025 San Antonio Breast Cancer Symposium
Oncotelic Therapeutics (OTCQB: OTLC) a biopharmaceutical company advancing transformative cancer therapies through its PDAOAI platform and expertise in nanomedicines, announced that Sapu Nano’s investigational intravenous Deciparticle(TM) everolimus (Sapu003) has been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, Dec. 9–12, 2025, in San Antonio, Texas. Developed by Sapu Nano, a joint venture between Oncotelic and Dragon Oversea, Sapu003 is a novel Deciparticle(TM) formulation of everolimus designed to improve bioavailability, reduce toxicity, and enhance tumor penetration in HR⁺/HER2⁻ metastatic breast cancer, RCC, and NET.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Oncotelic Therapeutics (OTCQB: OTLC) a biopharmaceutical company advancing transformative cancer therapies through its PDAOAI platform and expertise in nanomedicines, announced that Sapu Nano’s investigational intravenous Deciparticle(TM) everolimus (Sapu003) has been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, Dec. 9–12, 2025, in San Antonio, Texas. Developed by Sapu Nano, a joint venture between Oncotelic and Dragon Oversea, Sapu003 is a novel Deciparticle(TM) formulation of everolimus designed to improve bioavailability, reduce toxicity, and enhance tumor penetration in HR⁺/HER2⁻ metastatic breast cancer, RCC, and NET.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)